Phase 2Status unknownAge-related condition
ALT001 Phase II Dose-Finding Clinical Study for the Treatment of Amyotrophic Lateral Sclerosis
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Dose-ranging Study to Evaluate the Efficacy and Safety of ALT001 in Patients with Amyotrophic Lateral Sclerosis
- Sponsor
- Beijing Tiantan Hospital, Capital Medical University
- Enrolment
- 1 planned
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- ALT001 1; ALT001 2; the placebo
- Ages
- adults, older adults
- Registry
- ChiCTR2600132186
Full record on the Chinese Clinical Trial RegistrySource: WHO ICTRP, processed 14 September 2026
Primary outcomes
- Change from baseline in ALSFRS-R score at Week 24 of the DB period;
History
Last registry update
Registered
Started